All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The prognosis for patients with fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML) is poor, mainly due to early relapse and a lack of response to further treatment.1 Patients with FLT3-ITD AML in first complete remission often receive allogeneic stem cell transplantation (allo-SCT), however, relapse after allo-SCT has very low survival outcomes.2 The benefit of sorafenib as a monotherapy or in combination with other therapies in this setting remains unclear.
Professor Ali Bazarbachi, from the American University of Beirut, Beirut, LB, and colleagues published a report from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukaemia Working Party (ALWP), which assessed the safety and efficacy of sorafenib as a salvage therapy for adult patients with FLT3-ITD AML (n = 152) who relapsed or had disease progression following allo-SCT.3 This retrospective, registry-based, multicenter analysis examined the outcome of patients who received salvage therapy with sorafenib (n = 34; median age at allo-SCT = 48 years; range, 19–69) with patients who did not receive sorafenib salvage therapy (n = 118; median age = 51 years; range, 19–75). In addition, a pre-planned pair-matched analysis was also performed using data from 30 patients who had received sorafenib salvage compared to 30 patients who had not.
All findings shown as sorafenib group versus control group, where applicable
Based on this retrospective registry-based analysis the authors concluded that using sorafenib as a salvage therapy for patients with FLT3-ITD AML who relapsed or had disease progression following allo-SCT leads to improved survival. The administration of sorafenib as standard daily dose of 800 mg in two divided doses was safe, although dose modifications were frequently required.
References